CRDF - Cardiff Oncology - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CRDF is currently covered by 3 analysts with an average price target of $11.06. This is a potential upside of $8.83 (395.96%) from yesterday's end of day stock price of $2.23.

Cardiff Oncology's activity chart (see below) currently has 25 price targets and 32 ratings on display. The stock rating distribution of CRDF is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 25% with an average time for these price targets to be met of 183.83 days.

Highest price target for CRDF is $13, Lowest price target is $10, average price target is $11.

Most recent stock forecast was given by ROBERT BURNS from HC WAINWRIGHT on 05-Aug-2025. First documented stock forecast 17-Sep-2020.

Currently out of the existing stock ratings of CRDF, 5 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$10

$7.81 (356.62%)

2 months 16 days ago
(05-Aug-2025)

0/2 (0%)

$7.56 (309.84%)

Buy

$10

$7.81 (356.62%)

$7

10 months 9 days ago
(12-Dec-2024)

1/6 (16.67%)

$6.08 (155.10%)

547

Buy

$13

$10.81 (493.61%)

$14

11 months 14 days ago
(07-Nov-2024)

0/5 (0%)

$9.92 (322.08%)

Buy

$5

$2.81 (128.31%)

$6

3 years 25 days ago
(26-Sep-2022)

1/3 (33.33%)

$3.45 (222.58%)

533

Buy

$25

$22.81 (1041.55%)

$20

4 years 1 months 13 days ago
(08-Sep-2021)

0/2 (0%)

$18.01 (257.65%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CRDF (Cardiff Oncology) average time for price targets to be met?

On average it took 183.83 days on average for the stock forecasts to be realized with a an average price target met ratio 25

Which analyst has the current highest performing score on CRDF (Cardiff Oncology) with a proven track record?

JASON MCCARTHY

Which analyst has the current lower performing score on CRDF (Cardiff Oncology) with a proven track record?

ROBERT BURNS

Which analyst has the most public recommendations on CRDF (Cardiff Oncology)?

Jason Mccarthy works at MAXIM GROUP and has 0 price targets and 0 ratings on CRDF

Which analyst is the currently most bullish on CRDF (Cardiff Oncology)?

Naureen Quibria with highest potential upside - $22.81

Which analyst is the currently most reserved on CRDF (Cardiff Oncology)?

Jason Mccarthy with lowest potential downside - -$0

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?